The publication of positive preclinical data is a significant step for Corvus Pharmaceuticals. It indicates that the company's research and development efforts are yielding promising results, which could potentially lead to the development of new treatments for T cell-mediated inflammatory and immune diseases. This could have a positive impact on the company's stock as it indicates progress in their pipeline.